Neurosense Therapeutics Ltd. - Warrant (NRSNW) closed at $0.01 on November 5, 2026, down 59.2% from the previous close, on volume of 10,008 shares (30-day average 4,268).
Data as of November 5, 2026.
No headlines found.
NeuroSense to Strengthen PrimeC Canadian ALS Submission With New NfL Data
PRNewswire (Mon, 2-Nov 9:00 AM ET)
NeuroSense Files U.S. Patent Application for Traumatic Brain Injury
PRNewswire (Mon, 19-Oct 8:26 AM ET)
NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones
PRNewswire (Tue, 13-Oct 8:31 AM ET)
NeuroSense Provides Update on Nasdaq Listing Compliance
PRNewswire (Fri, 2-Oct 4:15 PM ET)
NeuroSense Provides Business Update and Progress for the First Half of 2026
PRNewswire (Fri, 25-Sep 4:30 PM ET)
NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference
PRNewswire (Thu, 10-Sep 9:00 AM ET)
Neurosense Therapeutics Ltd. - Warrant trades on the stock market under the symbol NRSNW.
As of November 5, 2026, NRSNW stock price declined to $0.01 with 10,008 million shares trading.
NRSNW has a market cap of $0.00. This is considered a Sub-Micro Cap stock.
In the last 3 years, NRSNW traded as high as $1.06 and as low as $.00.
NRSNW has underperformed the market in the last year with a price return of -98.2% while the SPY ETF gained +9.3%. NRSNW has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -95.5% and -20.9%, respectively, while the SPY returned -4.5% and -4.1%, respectively.
NRSNW support price is $.00 and resistance is $.02 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NRSNW shares will trade within this expected range on the day.
